ESH Video

5th International Conference Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment

5th International Conference Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment
October 24 - October 26, 2019 - Estoril, Portugal
Chairs : Hartmut Döhner, Bob Löwenberg, Martin Tallman


ESH 5th International Conference 
October 24-26, 2019 – Estoril, Portugal
Chairs: Bob Löwenberg, Hartmut Döhner, Martin Tallman

Programme description

The successful biannual ESH Conferences on acute myeloid leukemia (AML) have established themselves as scientific and educational programs at the interphase of molecular and biologic developments and clinical translation. Novel technological, molecular and immunologic approaches are rapidly creating novel insights into the biology and therapeutic perspectives of AML. The cutting-edge program of the conference will deal with the molecular and functional features of leukemic stem cells and their interaction with the microenvironment, the role of somatic and germ-line mutations and epigenetic alterations in the biology of AML, the genomics of leukemogenesis, advances in molecular diagnostics and developmental therapeutics with a focus on molecular and immunotherapeutic targeted therapeutics. Special attention will be given to the utility and promise of novel therapeutic agents.

Learning objectives

1. Understand the pathobiology of leukemia and its development with respect to alterations in hematopoietic stem cells, their microenvironment and altered signal transduction pathways.
2. Acquire insight into the possible mechanisms of inherited and preleukemic disorders and genomic instability that predispose to leukemogenesis and predispose also to disease progression.
3. Understand the characterization of a leukemia stem cell and its relationship to disease development and phenotype.
4. Learn about the pathobiologic importance of epigenetic dysregulation in the development of acute myeloid leukemia and its clinical impact.
5. Evaluate the merits and relevance of molecular diagnostics and minimal residual disease assessment in relation to various management decisions.
6. Gain insight into novel therapeutics of acute myeloid leukemia, including knowledge about their mechanisms of action, drug resistance mechanisms, the current developmental status of various targeted drugs and novel antibody-based and cell-transfer based immunotherapeutic approaches and their promises for future clinical application.

Why the meeting will be valuable for participants?

Cell biological, genomic and epigenetic studies have revealed entirely novel insights into the biology of AML, expanded the genomic landscape in unprecedented depth and discovered functional clues of dysregulation. These insights have furnished keys to the development of novel specifically acting therapeutic drugs and provide the opportunity to develop more effective risk adjusted therapeutic approaches. The emphasis of the Conference is on informal interaction among the participants and it intends to enable ample discussion. Scientific presentations by international leaders will provide the current status and a perspective of the exciting developments in the field. In separate sessions results from both basic and clinical research will be explored.

This meeting will be of interest to:

  • Ph-students, post docs, junior and senior biologists and practicing clinicians (MD, PhD, MD-PhD), hematologists and oncologists in training
  • Residents and biologists still in-training


Abstract submission





Thursday, October 24th from 12:40 to 1:40 pm:
AML Treatment in 2019: Where Are We Now and Where Are We Headed?
SPEAKERS: Konstanze Döhner (Ulm), Amer Zeidan (New Haven)
This symposium is organized and funded by Novartis.

Friday, October 25th from 8:00 to 9:00 am:
The enigma of high-risk AML*
*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
SPEAKERS: Lars Bullinger (Berlin), Donald McLornan (London)
This promotional symposium is funded and organised by Jazz Pharmaceuticals

Friday, October 25th from 1:35 to 1:35 pm:
Expert insights on the rapidly evolving FLT3-positive AML treatment landscape
CHAIR: Paresh Vyas (Oxford)
SPEAKERS: Naval Daver (Houston), Konstanze Döhner (Ulm)
This symposium is organised and funded by Daiichi Sankyo Europe GmbH


Accommodation at special conference rates is available nearby the Estoril Congress Center, where the conference will take place.

In order to help with your planning, a number of rooms have been blocked by Forum d’Ideias PCO.

Individual reservations can be made via the online registration booking system. You need to register first, to enable the access to the accommodation. To book your room, please click here.


For group bookings, please send your request in writing to


Estoril Congress Center
Av. Amaral,
2765-192 Estoril, Portugal

Estoril is located on the Portuguese coast at about a half hour drive from Lisbon International airport (

Corporate partners

With the support of



Diamond Conference Partners





Emerald Conference Partners





Ruby Conference Partners




Please contact:




Scholarships and travel grants are available for this meeting. You are eligible to apply if:

  1. You are an early-career scientist (fully trained or in training, up to six years since first junior faculty position). No geographic restrictions apply to these scholarships. Click here for further information Extended deadline to submit your application: July 21st, 2019


  1. You are a fully trained clinical haematologist or a senior clinical resident working in Europe. Click here for further information  Deadline to submit your application: September 1st, 2019


Educational Grants


The registration fee for the ESH 5th International Conference on AML is:
– 600€  for fully trained
– 300€ for in-training

A proof will be requested to confirm your status.

This fee includes:
Your seat in the Conference Room
The conference materials,
Welcome cocktail, luncheons, refreshments throughout the conference.

Your seat in the conference will be definitively reserved upon receipt of your fee.


How to proceed :
Please make sure that your Internet browser (Firefox, Internet Explorer, Safari, Google Chrome…) is up-to-date. Using an old version may prevent you from visualising the full website content.

A) For Individual Registration:
1. Click on REGISTER HERE at the bottom of the page
3. Create an account and complete the registration form. It is very important to use the email of the participant in the form.
4. Proceed with the payment.

B) For Group Registration (More than one person):
1. Click on REGISTER HERE at the bottom of the page
3. Create an account and fill in the complete details for each person that you would like to register (Use the personal email address of each participant you are registering, failure to do so will prohibit you from completing the registrations.)
4. Proceed with payment.

Cancellation policy of registration fee
In case of cancellation, up until two months prior to the beginning of the meeting, your registration fee will be reimbursed in full (less bank charges). If the cancellation is notified between 60 to 15 days prior to the beginning of the meeting, 50% of the registration fee will be reimbursed (less bank charges). Cancellations notified 15 days before the meeting will not be reimbursed. For credit card payments please register on-line first. Please note that ESH can accept VISA, MASTERCARD/EUROCARD, AMEX and CB.

Register Here